The following projects are available for partnering in the field of epigenetic enzymes:
HDAC inhibitor scaffolds with binding kinetic signatures
An in-depth understanding of the mechanism of action for HDAC allowed the new two-dimensional design of inhibitors. We have developed eight non-hydroxamate zinc-binding proprietary scaffolds with pre-engineered structural features for long residence times.
HKMT inhibitors with improved selectivity
Mercachem and Proqinase have received a €2.5 million grant from Eurostars to develop new HKMT inhibitors. The development of a proprietary scaffold linker has resulted in compounds with improved EHMT1/EHMT2 selectivity. Currently, iterative library synthesis is ongoing to further explore the bioactive space around the hit compounds.